ED-LP02-02
Age, ovarian reserve markers, and basic medical history often travel together in egg donor screening because each one answers a different question. None of them is a full verdict on your future, and none should be read like a single score that decides everything by itself.
Why these factors are reviewed together
Age, AMH, antral follicle count, and medical history are often discussed together because they help a program understand readiness and safety. Age may shape how a program thinks about donor fit. AMH and AFC can help estimate ovarian response. Medical history explains whether anything about the cycle may need more review.
That does not make any one of those items a universal pass or fail. A thoughtful donor screen is looking for a clearer picture, not a shortcut. The aim is to understand whether the donor candidate is likely to be safe to evaluate further and whether the interpretation should stay cautious.
What a donor should ask about results
If a program gives you a number or a preference, ask what it is being used for. Is it helping with likely response, with cycle safety, or with a program policy question? Ask whether the program wants a repeat test, a baseline ultrasound, or a follow-up consult before it can say anything more.
It is also fair to ask whether the same result would mean the same thing in a different clinic. A good screening conversation should make the difference between a marker and a decision feel obvious rather than mysterious.
- What does this marker help the program decide?
- Is this a screening question or a final decision?
- Would the result be read differently with a different lab or clinic?
- Do I need a repeat test or another consult?
AMH, AFC, and basic history are planning tools
AMH is a blood test that is often discussed because it can help estimate ovarian response, especially when the program is thinking about stimulation planning. Antral follicle count is a transvaginal ultrasound measure that counts small follicles early in the cycle and gives another view of ovarian activity. Day-3 FSH and estradiol may also appear in some programs, especially when the team wants more baseline context. None of those markers is a perfect stand-alone answer.
A basic medical-history review adds the context those markers need. Prior surgery, medications, cycle history, and family history can affect how a clinician reads the file. A high-quality donor screen asks what the marker can change, what it cannot prove, and whether the next step is more testing or a conversation with a reproductive endocrinologist.
For Nerds: Technical Deep Dive
This advanced section explains why donor screening often uses age, AMH, AFC, and baseline history together. It makes the interpretive boundary explicit: these are planning tools for ovarian response and safety review, not universal measures of donor value or guaranteed retrieval performance.
Ovarian reserve markers are context markers
A technically literate donor-screening discussion should treat age, AMH, and antral follicle count as separate kinds of information. Age is a broad demographic and biological context marker. AMH is a blood-based marker that can help a clinician estimate ovarian response, especially when deciding whether stimulation planning needs to be cautious. Antral follicle count is an ultrasound-based count that reflects the small follicles visible at baseline and can help corroborate or complicate the AMH story. Day-3 FSH and estradiol may appear in some screening workflows when a clinic wants a more traditional baseline picture. The expert-grade point is that these markers are not interchangeable. A donor with a reassuring AMH can still need more review if history raises a safety question. A donor with a lower AMH can still have a conversation about eligibility if the broader file is otherwise acceptable and the program is willing to proceed. What matters is the clinical question being asked: likely response, cycle safety, or whether the program should pause for further review. That is why public education should avoid translating one marker into a moral or personal score. The right explanation is that ovarian reserve markers help with planning, but they do not create certainty about retrieval yield, embryo quality, or long-term reproductive destiny.
- AMH helps with response planning but does not stand alone.
- AFC depends on ultrasound timing and operator technique.
- Day-3 FSH and estradiol are contextual baseline markers, not universal donor cutoffs.
Expected ranges / examples
- Age example used in public donor education: 21-34 years. Example donor-age language used in public patient education; must remain program- and jurisdiction-aware. Source: ReproductiveFacts.org - Third-Party Reproduction booklet.
Timeline breakdown
- Baseline intake: Before any stimulation decision. Age and medical history are reviewed to decide whether reserve markers or ultrasound are needed next.
- Reserve assessment: Before screening is finalized. AMH and AFC are interpreted together so the program can decide whether the file needs more context.
- Follow-up interpretation: After initial results are back. A clinician decides whether the markers are reassuring enough to continue or whether another consult is more appropriate.
Key takeaways
- Age, AMH, AFC, and history are read together.
- One number does not decide your donor candidacy.
- Ask what each result changes before you treat it like a verdict.
FAQ
Does AMH decide whether I can donate?
No. AMH can help a clinician think about ovarian response, but eligibility still depends on the whole screen, including history and program rules.
Why ask about surgery and medication history?
Because those details can change how a program interprets your file and whether more review is needed before screening continues.
Should I treat one number as my answer?
No. In donor screening, numbers are usually planning tools, not a complete verdict.